The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
SERES THERAPEUTICS INC COM 81750R102 93,092 12,682,876 SH   DFND 2 0 12,682,876 0
SYROS PHARMACEUTICALS INC COM 87184Q107 41,594 3,204,437 SH   DFND 2 0 3,204,437 0
QUANTERIX CORP COM 74766Q101 34,600 2,030,495 SH   DFND   0 2,030,495 0
DENALI THERAPEUTICS INC COM 24823R105 175,610 8,918,749 SH   DFND 1 0 8,918,749 0